

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 2<sup>nd</sup> July 2025**

**FOI Ref No 29418**

**Requested Information:**

1.
  - a. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
  - b. Of these patients, how many commenced treatment at your trust within the last 6 months?
  
2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
  - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
  - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
  - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
  - Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
  - R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
  - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
  - R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
  - (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
  - R-GemOX (rituximab, gemcitabine and oxaliplatin)
  - Axicabtagene ciloleucel
  - Tisagenlecleucel
  - Epcoritamab
  - Loncastuximab tesirine
  - Glofitamab
  - Any other SACT
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)

3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
  - Axicabtagene ciloleucel (Yescarta)
  - Tisagenlecleucel
  - Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
  - R-GemOX (rituximab, gemcitabine and oxaliplatin)
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  - Any other treatments
  
4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?
  
5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
  - CAR-T Therapy (E.g. Axicabtagene ciloleucel)
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic)
  - Any other treatment

### Response:

1.
  - a. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? **22**
  - b. Of these patients, how many commenced treatment at your trust within the last 6 months? **22 1<sup>st</sup> txt start**
  
2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
  - R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) **10**
  - R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) **6**
  - Pola-BR (polatuzumab vedotin with rituximab and bendamustine) **1**
  - Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) **9**

- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) **0**
  - R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) **0**
  - R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) **0**
  - (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) **1**
  - R-GemOX (rituximab, gemcitabine and oxaliplatin) **2**
  - Axicabtagene ciloleucel – **RCHT is not a centre that can use this drug but 4 referred to other centres**
  - Tisagenlecleucel – **RCHT is not a centre that can use this drug**
  - Epcoritamab **3**
  - Loncastuximab tesirine – **RCHT is not a centre that can use this drug**
  - Glofitamab **4**
  - Any other SACT – **Cytarabine, Methotrexate, Rituximab + Thiotepa (1), R-CEOP (1), R-CE (1), trial (1)**
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic) **0**
3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
- Axicabtagene ciloleucel (Yescarta) – **RCHT is not a centre that can use this drug but 2 referred to other centres**
  - Tisagenlecleucel – **RCHT is not a centre that can use this drug**
  - Pola-BR (polatuzumab vedotin with rituximab and bendamustine) **1**
  - R-GemOX (rituximab, gemcitabine and oxaliplatin) **2**
  - Stem cell transplant or bone marrow transplant (autologous or allogeneic) **0**
  - Any other treatments **0**
4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)? **7**
5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
- CAR-T Therapy (E.g. Axicabtagene ciloleucel) **4 (2 at 2<sup>nd</sup> line, 2 at 3<sup>rd</sup> line)**

- Stem cell transplant or bone marrow transplant (autologous or allogeneic) **0**
- Any other treatment **0**

**Attachment(s):**

No Attachment(s)

**Date Response sent: 17<sup>th</sup> July 2025**